Karuna Therapeutics
NEWS
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
Funding to drive investigation of further potential indications for lead product candidate, KarXT First U.S. Patent awarded for KarXT
The latest financing round will boost the study of KarXT, Karuna’s lead product candidate, which is currently in Phase II development as a potential treatment for acute psychosis in patients with schizophrenia.
Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.
Days after it closed on a $42 million Series A funding round, Karuna Pharmaceuticals has named a new chief executive officer. The company appointed industry veteran and founder of Sage Therapeutics Steven Paul as its new top officer.
Boston-based biotech company Karuna Pharmaceuticals completed a $42 million Series A financing. The round included the issuance of $22 million in shares upon conversion of debt into equity.
Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.
JOBS
IN THE PRESS